Analysts Offer Insights on Healthcare Companies: Synlogic Inc (SYBX) and HTG Molecular Diagnostics (HTGM)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Synlogic Inc (SYBX) and HTG Molecular Diagnostics (HTGM) with bullish sentiments.

Synlogic Inc (SYBX)

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Synlogic Inc today and set a price target of $18. The company’s shares closed on Friday at $7.99, close to its 52-week low of $7.27.

Breidenbach said:

“At the 2018 SITC meeting, Synlogic presented new preclinical data on SYNB-1891, a first-in-class living drug designed to elicit durable tumor immunity when injected into tumors. The company hosted an investor event detailing how its synthetic biotic is substantially differentiated from small molecule agonists of STING and TLR pathways. Specifically, SYNB-1891 is capable of mounting a two-pronged activation of type I interferon (IFN) response which leads to robust T cell activation, anti-tumor response, and protection from tumor re-challenge in murine models. While our valuation of Synlogic remains focused on the company’s clinical-stage programs for metabolic disorders (SYNB-1020 and SYNB-1618), we believe the new data presented at SITC highlights the versatility of the company’s technology platform. Reiterate Outperform, $18 PT.”

According to TipRanks.com, Breidenbach is a 3-star analyst with an average return of 2.7% and a 38.4% success rate. Breidenbach covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Sorrento Therapeutics, and Seres Therapeutics.

Synlogic Inc has an analyst consensus of Strong Buy, with a price target consensus of $21.33.

See today’s analyst top recommended stocks >>

HTG Molecular Diagnostics (HTGM)

In a report released today, Mark Massaro from Canaccord Genuity maintained a Buy rating on HTG Molecular Diagnostics, with a price target of $6. The company’s shares closed on Friday at $3.65.

Massaro noted:

“We recently hosted 3 days of investor meetings with HTG CEO TJ Johnson and CFO Shaun McMeans, and came away feeling positive about the company’s increased visibility to its business and positioning as a precision medicine enabler in the less-crowded RNA profiling market. Additionally, on its Q3/18 call, HTG delivered an encouraging update highlighted by its continued progress toward signing one or more companion diagnostics agreements with pharma. HTG’s stock is up ~80% YTD, but has pulled back ~32% from its high in late September. For investors able to invest in a micro-cap and handle short- term volatility, we think HTG is an inexpensive way to invest in a precision medicine pure-play, trading at just ~3.5x and ~2.6x our FY’19 and FY’20 revenue estimates, respectively.”

According to TipRanks.com, Massaro is a 5-star analyst with an average return of 16.1% and a 56.7% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Meridian Bioscience Inc, Quanterix Corporation, and Orasure Technologies.

HTG Molecular Diagnostics has an analyst consensus of Strong Buy, with a price target consensus of $6.75, an 84.9% upside from current levels. In a report issued on November 9, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $7 price target.

.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts